GSK PLC Sponsored ADR $GSK Shares Sold by Douglas Lane & Associates LLC

Key Points

• Douglas Lane & Associates LLC reduced its holdings in GSK PLC Sponsored ADR by 13.4%, owning approximately 1.32 million shares valued at $50.58 million.
• GSK recently reported earnings of $1.23 EPS, beating analyst estimates, with a revenue of $10.64 billion, reflecting a 1.3% increase from the previous year.
• The company declared a quarterly dividend of $0.4206, with an annualized yield of 4.1%, despite a payout ratio of 77.78%.

Douglas Lane & Associates LLC lessened its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 13.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,317,109 shares of the pharmaceutical company's stock after selling 204,417 shares during the period. Douglas Lane & Associates LLC owned 0.06% of GSK worth $50,577,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. NewEdge Advisors LLC lifted its holdings in shares of GSK by 8.6% in the first quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company's stock valued at $3,512,000 after purchasing an additional 7,148 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of GSK by 201.9% in the first quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company's stock valued at $154,244,000 after purchasing an additional 2,663,270 shares in the last quarter. Everstar Asset Management LLC raised its position in shares of GSK by 230.3% in the first quarter. Everstar Asset Management LLC now owns 26,300 shares of the pharmaceutical company's stock valued at $1,019,000 after buying an additional 18,337 shares during the last quarter. Fred Alger Management LLC raised its position in shares of GSK by 16.7% in the first quarter. Fred Alger Management LLC now owns 51,693 shares of the pharmaceutical company's stock valued at $2,020,000 after buying an additional 7,390 shares during the last quarter. Finally, First Hawaiian Bank raised its position in shares of GSK by 18.8% in the first quarter. First Hawaiian Bank now owns 101,039 shares of the pharmaceutical company's stock valued at $3,914,000 after buying an additional 15,987 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Down 0.2%

Shares of GSK stock traded down $0.06 on Thursday, hitting $40.30. The stock had a trading volume of 2,019,474 shares, compared to its average volume of 5,023,627. The firm has a market capitalization of $82.08 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 2.00 and a beta of 0.53. The stock's 50 day moving average is $38.84 and its 200-day moving average is $38.52. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $42.63.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. During the same period in the prior year, the firm earned $0.43 earnings per share. The business's quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio is 77.78%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.